A robust pipeline with four assets expected in the clinic by 2027 targets high unmet needs in oncology and fibrotic diseases, supported by strong R&D, strategic partnerships, and a solid financial position. Multiple near-term catalysts and blockbuster opportunities are anticipated.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.